I can extract side effects

Wei Kang's side is in a very good mood. This time, the only company in the world with AD special effects drugs has created such a great momentum. He is out of his mind to authorize the drug.

As an adult, of course it is best to hold it firmly in your own hands.

The previous anti-cancer drug, Sanqing was still very weak at the time. It needed money but no money, and no one needed people. Get a return on your investment.

Naturally, there is no rush now. Sanqing is already a large pharmaceutical company, with money, people, and various resources. Of course, we have to do it ourselves, relying on the grandeur of the situation, to promote the overseas market with all our strength.

Generally speaking, to enter the market of various countries, it is necessary to apply to the local drug regulatory department, and the standards and regulations adopted in different regions are different. Entering the Eagle Country market requires passing the FDA, entering the Huaxia market requires passing the CFDA, entering the Europa market requires CE certification, and entering the Maoxiong market also requires medical registration.

And the authority of the FDA is reflected. A drug approved by the FDA can almost open the door to most overseas countries. Although other countries also have their own drug review standards, they basically refer to the clinical data and standards of the FDA. .

There are probably several corresponding strategies for domestic pharmaceutical companies to enter the overseas pharmaceutical market, especially the Eagle Country market.

The first is to authorize joint development, commonly known as License Out.

Enterprises with high-value R\u0026D products often choose to jointly develop and promote products with local pharmaceutical companies in order to accelerate the approval of overseas R\u0026D. This cooperation model can obtain direct benefits due to milestone payments, and is the model chosen by most domestic pharmaceutical companies. .

Because the research and development of new drugs is often close to death, the investment is huge, and many pharmaceutical companies cannot survive. Therefore, as soon as there is a result, the cost must be recovered as soon as possible, and authorized development is undoubtedly the best choice.

Sanqing’s previous anticancer drugs chose such a model.

Other domestic pharmaceutical companies also have many classic cases in this regard.

For example, in 2013, BeiGene and Merck Serono signed a global cooperation agreement to jointly develop the second-generation BRAF inhibitor BGB-283, which brought a lot of money to BeiGene at a critical moment. At the critical moment, Baiji Shenzhou was saved.

The second is to set up overseas companies for independent research and development.

Some pharmaceutical companies have strong comprehensive strength and often choose to report to the FDA by themselves. If the drug is approved, the rights and interests will belong to them. At present, some large domestic pharmaceutical companies have obviously tasted the sweetness and have made continuous efforts in this regard, with fruitful results.

For example, Hengrui Medicine, a leading domestic pharmaceutical company, has established a subsidiary, Hengrui Therapeutics, in Eagle Country to engage in project introduction and drug discovery activities. The company's drug pipeline initially includes three tumor candidates, pyrotinib, SHR-A1201, and SHR1210 (PD1 monoclonal antibody drug) isolated from Hengrui.

In 2016, the company received US$100 million investment from Hengrui Medicine and an undisclosed blue-chip investment institution. Over the past 17 years, among Hengrui Medicine's four innovative drugs approved for clinical use in Eagle Country, three have been declared by its subsidiary Hengrui Therapeutics.

The third, and last, is to apply for domestic funding.

Such companies often refer to generic drug companies, and the declared varieties are generic drugs. The declaration of generic drugs is simpler than that of innovative drugs. Companies often do not choose to establish overseas subsidiaries, and there is no authorization for generic drugs. Therefore, most companies choose to report to the FDA in China, or choose a suitable Eagle Country service agency to assist in the declaration.

This is because the original drugs of overseas pharmaceutical companies are very expensive, so the FDA will open clinical applications to cheap and high-quality generic drugs from some other countries and approve them for marketing to reduce the burden on patients.

Just like the well-known Tianzhu Country generic drug, it is very popular in Eagle Country, and has already occupied 42% of the local generic drug market share.

There are also many domestic pharmaceutical companies. For example, HEC Pharmaceuticals submitted an ANDA (ie, Eagle Country Generic Application) new drug application for a hypoglycemic drug Liagliptin to the FDA last year and was approved.

After formulating a strategy for overseas expansion, it is approved by the FDA and other national drug regulatory agencies.

The follow-up commercial development of new drugs is also very important, mainly divided into two parts: promotion and sales.

After the drug is approved by the FDA, those products that have been authorized to be transferred and have overseas partners will be distributed through the partners for market development. For most of the pharmaceutical companies that have not cooperated before approval, they choose to carry out distribution and marketing by themselves. Terminal pharmacy development.

Subsequent development is divided into two aspects, just like a person's left and right legs, both of which are indispensable, and both aspects need to be exerted at the same time to develop the commercial sales of drugs to the greatest extent possible.

One aspect is overall branding.

The so-called soldiers and horses do not use food and grass first. After the drug is approved, it needs the strong support of KOL public figures, whether in China or overseas.

In China, pharmaceutical companies will invite doctors to host or participate in launch meetings to lay the foundation for future products.

Also in Eagle Country, before and after the drug is approved, the overall marketing of the drug is a necessary work content of the company.

In addition to educating the market and letting more doctors and patients know about the approval of the product, the extensive information exposure on social media also paves the way for the later search for distributor partners and increases the bargaining chip for negotiations.

In terms of promotion focus, innovative drugs emphasize the advantages and value of drugs, while generic drugs emphasize the cost-effectiveness of drugs. The price war has a natural advantage for Huaxia, a rising star.

Another aspect is to find partners, including distributors, pharmacies and hospitals.

Except for the top companies that have been approved by domestic pharmaceutical companies, most pharmaceutical companies have a relatively weak foundation in this area and need to continue to accumulate.

Enterprises can find partners by themselves, or choose to cooperate with professional service organizations to complement each other's advantages, and buy time to establish cooperation with local distributors as soon as possible and let the products achieve sales performance as soon as possible.

The pharmaceutical sales market in overseas countries is very different from that in China. Most of the domestic medicines are controlled by hospitals, and pharmacies only serve as supplements for some over-the-counter medicines.

In the pharmaceutical market like Eagle Country, the drugs used by hospitals are mainly concentrated on the inpatient side, and the retail side consisting of distributors and retail pharmacies is the bulk of drug sales.

In 2018, Eagle Country's medical expenditures reached 18.9% of the country's GDP, or US$3.7 trillion, of which prescription drug expenditures accounted for 12%. The entire prescription drug market is about 440 billion U.S. dollars, with 12 prescriptions issued per capita per year, and per capita consumption of 1150 U.S. dollars.

Patients in Eagle Country seek medical treatment from doctors. Doctors can only write prescriptions, and cannot sell medicines in hospitals or their own clinics. Patients can go to any pharmacy to buy the medicines they need after getting prescriptions. The cost is borne by patients and insurance (government medical insurance) + business insurance) paid pro rata.

The process is very simple, but the drug sales system behind it is very complicated, reflecting a complex chain of interests.

In the entire drug sales chain, pharmaceutical companies earn about 70% of the revenue. Some analysts believe that the profits of Yingguo's patented drugs even exceed those of the tobacco industry.

Monopoly operation, free pricing and insurance payment have made Eagle Country the largest drug consumer country and the international status of the largest drug market. Pharmaceutical manufacturers all over the world yearn to try their hand at the Eagle Country.

Soon after, Sanqing issued another announcement on its official website, announcing the official establishment of Sanqing's overseas subsidiary.

"Sanqing Pharmaceutical's overseas subsidiary has been formally established recently, and it is recruiting talents. We welcome capable, courageous, and aggressive pharmaceutical talents to apply for the job and join us in this grand event."

"The internationalization process of domestic pharmaceutical companies is like a river going east and west, and we are moving forward in this torrent. In the near future, Sanqing Pharmaceutical's overseas sales market will continue to break through and reach new heights. And then create a truly world-class pharmaceutical company.”

This time Sanqing went overseas, in addition to clinical declaration work, expanding overseas distributors and retail pharmacies, and building a local sales force are the top priorities.

At the same time, a wave of international talent recruitment has also been carried out. Due to the reputation of the new drug with special effects for Alzheimer's disease, many industry talents have heard the news and come to invest one after another.

At the same time, countries have also announced the news of the introduction of Sanqing AD specific drugs for the first time.

In terms of approval procedures, they are all passed at the fastest speed, striving to start clinical trials as soon as possible and speed up the listing process.

Patients and their families in Western countries are also relieved when they learn that the new drug will finally start phase III clinical trials.

They went to relevant hospitals and clinical research institutions to apply.

After all, they have been making trouble for so long, isn't it just to participate in clinical trials as soon as possible?

Now, patients can't wait, and they are waiting for this new drug to save their lives.